Organisation paid for research Program year 2025 Source: CMS Open Payments

Endocrine Research Solutions Inc

Neither a doctor nor a teaching hospital

Research payments

$1,659,863

363 payments

Through program year 2025, Endocrine Research Solutions Inc is reported as receiving $1,659,863 in research payments, across 363 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$184,274	157
2024	Research	$31,921	5
2023	Research	$74,334	22
2022	Research	$149,446	10
2021	Research	$307,509	15
2020	Research	$55,891	34
2019	Research	$856,490	120

Breakdown

Who paid Research payments · program years 2019–2025

Novo Nordisk AS $700,389 100 payments
Eli Lilly and Company $639,858 36 payments
Sequel Med Tech, LLC $172,687 154 payments
Sanofi US Services Inc. $102,998 50 payments
Pfizer Inc. $34,221 19 payments
AbbVie, Inc. $5,692 1 payment
Boehringer Ingelheim Pharmaceuticals, Inc. $3,000 2 payments
Lexicon Pharmaceuticals, Inc. $1,019 1 payment

Studies the money was for Research payments · program years 2019–2025

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-4) $268,989 5 payments
Nn9536-4373 $201,827 12 payments
A Phase 2, Randomized, Parallel, Open-Label Comparator Controlled Trial to Evaluate the Safety and Efficacy of Ly3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy $186,437 6 payments
Innovative Automated Insulin Delivery System for T2D $172,687 154 payments
Nn9536-4375 $133,577 14 payments
A Prospective, Randomized, Double-Blind Comparison of Ly900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion $103,994 3 payments
Nn9536-4376 $78,121 12 payments
Nn9536-4374 $76,075 12 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk $35,396 12 payments
Ex9924-4473 $33,045 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.